Intraocular microinjections repair experimental Parkinson's disease

Brain Research

Volumn 1217, Issue , 2008, Pages 119-131

  Willis, Gregory L ^a  

^a Neurosciences Section   (Australia)

Author keywords

Circadian; Dopamine; Intravitreal; Melatonin; Parkinson's disease; Retino hypothalamic tract

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA; MELATONIN; N (2,4 DINITROPHENYL) 5 METHOXYTRYPTAMINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BIOAVAILABILITY; BODY WEIGHT; CHI SQUARE TEST; CONTROL GROUP; HISTOLOGY; LIGHT DARK CYCLE; MOTOR PERFORMANCE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHOTOTHERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RAT; RETINA CELL; STATISTICAL SIGNIFICANCE; SUBSTITUTION THERAPY;

5-METHOXYTRYPTAMINE; ANIMALS; ANTIPARKINSON AGENTS; CIRCADIAN RHYTHM; LEVODOPA; MALE; MICROINJECTIONS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RETINA;

PARKINSONIA;

EID: 45449117458     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.03.083     Document Type: Article

References (65)

1. Abbott A. While you were sleeping. Nature 437 (2006) 1220-1222
2. Abilio V.C., Vera Jr. J.A., Ferreira L.S., Duarte C.R., Carvalho R.C., Grassl C., Martins C.R., Torres-Leite D., Bignotto M., Tufik S., Ribeiro Rde A., and Frussa-Filho R. Effect of melatonin on orofacial movements in rats. Psychopharmacology 161 4 (2002) 240-347
3. Akhisaroglu M., Ahmed R., Kurtuncu M., Manev H., and Uz T. Diurnal rhythms in cocaine sensitization and on period 1 levels are common across rodent species. Pharmacol. Biochem. Behav. 79 1 (2004) 37-42
4. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., Lacomblez L., Golmard J.L., Derenne J.P., and Agid Y. Parkinson's disease and Sleepiness. An integral part of PD. Neurology 58 (2002) 1019-1024
5. Artemenko A.R., and Levin Y.I. Light therapy of patients with Parkinsonism. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 96 3 (1996) 63-66
6. Balagura S., Wilcox R.H., and Coscina D.V. The effects of diencephalic lesions on food intake and motor activity. Physiol. Behav. 4 (1969) 629-633
7. Bellastella A., Parlato F., and Sinisi A.A. Blindness impairs plasma growth hormone responses to l-dopa but not to arginine. J. Clin. Endocrinol. Metab. 70 4 (1990) 856-858
8. Blazejova K., Nevsimalova S., Illnerova H., Hajek I., and Sanka K. Sleep disorders and the 24 hour profile of melatonin and cortisol. Sb. Lek. 101 4 (2000) 347-351
9. Boeve B.F., Silber M.H., and Ferman T.J. REM sleep behaviour disorders in Parkinson's disease and dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol. 17 (2004) 146-157
10. Bordet R., Devos D., Brigue S., Touitou Y., Guieu J.D., Libersa C., and Destee A. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 26 2 (2003) 65-72
11. Borg D.C. Free radicals in the human nervous system. Adv. Neurol. 5 (1974) 277-286
12. Catala M.D., Canete-Nicolas C., Fradi A., Tara Zona P.J., Tormos J.M., and Pascual-Leone A. Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. 32 4-5 (1997) 553-558
13. Demet E.M., Chicz-Demet A., Fallon J.H., and Sokolski K.N. Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 5 (1999) 753-784
14. Deniker P., Ginestet D., and Loo H. Psychotropic drugs and mechanisms of mood regulators. Encephale 1 4 (1975) 359-362
15. Djamgoz M.B.A., Hawkins M.W., Hirano J., and Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vis. Res. 37 24 (1997) 3509-3529
16. Dowling G.A. Sleep in older women with Parkinson's disease. J. Neurosci. Nurs. 27 6 (1995) 355-362
17. Dubocovich M.L. Melatonin is a potent modulator of dopamine release in the retina. Nature (London) 306 (1983) 782
18. Dubocovich M.L. Role of melatonin in the retina. Prog. Retinal Res. 8 (1989) 129-151
19. Ebadi M., and Govitrapong P. Neural pathways and neurotransmitters affecting melatonin synthesis. J. Neural Transm. (Suppl) 21 (1986) 125-155
20. Fahn S., and Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease. J. Neurol. 252 Suppl. 4 (2003) IV37-IV42
21. Fink J.S., and Smith G.P. L-dopa repairs deficits in locomotor and investigatory exploration produced by denervation of catecholamine terminal fields in the forebrain of rats. J. Comp. Physiol. Psychol. 93 (1979) 66-73
22. Ghaemi M., Rudolf J., Hilker R., Herholz K., and Heiss W.-D. Increased pineal F-dopa uptake is related to severity of Parkinson's disease - A PET study. J. Pineal Res. 30 (2001) 213-219
23. Girotti F., Carella F., Grassi M.P., Soliveri P., Marano R., and Caraceni T. Motor and cognitive performances of Parkinsonian patients in the on and off phase of the disease. J. Neurol. Neurosurg. Psychiatry 49 6 (1986) 657-660
24. Guardiola-Le Maitre B. Toxicology of melatonin. J Biol Rhythms 12 60 (1997) 697-706
25. Hadjiconstantinou M., and Neff N.H. Catecholamine systems of retina: a model for studying synaptic mechanisms. Life Sci. 35 (1984) 1135-1147
26. Huerto-Delgadillo L., Anton-Tay F., and Benitez-King G. Effect of melatonin on microtubule assembly depends on hormone concentration: role of melatonin as a calmodulin antagonist. J. Pineal Res. 17 (1994) 55-62
27. Kremer H.P. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases. Prog. Brain Res. 93 (1992) 249-261
28. Langston J.W., and Forno L.S. The hypothalamus in Parkinson's disease. Ann. Neurol. 3 2 (1978) 129-133
29. Ljungberg T., and Ungerstedt U. Reinstatement of eating by dopaminergic agonists in aphagic dopamine denervated rats. Physiol. Behav. 16 (1976) 277-283
30. Lorefalt B., Ganowiak w., Palhagen S., Toss G., Unosson M., and Granerus A.K. Factors of importance for weight loss in elderly patients with Parkinson's disease. Acta Neurol. Scand. 110 3 (2004) 180-187
31. Manev H., and Uz T. Clock genes: influencing and being influenced by psychoactive drugs. Trends Pharmacol. Sci. 27 4 (2006) 186-189
32. Medeiros C.A., Carvelhedo de Bruin P.F., Lopes L.A., Magalhaes M.C., de Lourdes Seabra M., and Sales de Bruin V.M. Effects of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease: a randomized, double blind, placebo-controlled study. J. Neurol. 254 4 (1996) 459-464
33. Moore R.Y. Neural control of the Pineal gland. Behav. Brain Res. 73 (1996) 125-130
34. Moore R.Y., and Bloom F.E. Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Annu. Rev., Neurosci. 1 (1978) 129-169
35. Moore R.Y., Heller A., Wurtman R.J., and Axelrod J. Visual pathways mediating pineal response to environment light. Science 155 (1967) 220-223
36. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottlieb G.L., and Joyce J.N. damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with Parkinsonism. Ann. Neurol. 37 3 (1995) 300-312
37. Nutt J.G., Woodward W.R., Carter J.H., and Gancher S.T. Effect of long-term therapy on the pharmacodynamics of levodopa. Arch. Neurol. 49 (1992) 1123-1130
38. Okun M.S., and Watts R. Depression associated with Parkinson's disease. Clinical factors and treatment. Neurology 58 Suppl 1 (2002) 563-570
39. O'Neill R.D. Uric acid levels and dopamine transmission in rat striatum: diurnal changes and effects of drugs. Brain Res. 507 2 (1990) 267-272
40. Papavasiliou P.S., Cotzias G.C., Dölby S.E., Steck A.J., Bell M., and Lawrence W.H. Melatonin and Parkinsonism. JAMA 221 1 (1972) 88-89 (July 3)
41. Parkinson J. An essay on the shaking palsy (1817), Whittingham and Rowland, London
42. Paus S., Schmitz-Hübsch T., Klockgether T., and Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov. Disord. 22 10 (2006) 1495-1498
43. Pellegrino L., Pellegrino A., and Cushman A. A stereotaxic atlas of the rat brain (1979), Plenum Press, New York
44. Schmid H.A. Decreased melatonin biosynthesis, calcium flux, pineal gland calcification and aging: a hypothetical framework. Gerontology 39 (1993) 189-199
45. Schorderet M., and Nowak J.Z. Retinal dopamine D1 and D2 receptors: characterization by binding or pharmacological studies and physiological functions. Cell. Mol. Neurobiol. 10 3 (1990) 303-325
46. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., Elizur A., and Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind placebo-controlled, crossover study. Arch. Gen. Psychiatr. 58 11 (2001) 1049-1052
47. Shaw K.M. Hypothalamo-pituitary-adrenal function in Parkinsonian patients and patients treated with melatonin. Curr. Med. Res. Opin. 4 10 (1977) 743-746
48. Shaw K.M., Stern G.M., and Sandler M. Melatonin and Parkinsonism. Lancet, 1 (1973) 271
49. Shaw K.M., Stern G.M., and Sandler M. Melatonin and metatyrosine in the treatment of Parkinsonism. Adv. Neurol. 3 (1975) 115
50. Shrinivasan V., Pandi-Peruma S.R., Maestroni G.J., Esquifino A.I., Hardeland R., and Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotox. Res. 7 4 (2005) 293-318
51. Uretsky N.J., and Schoenfeld R.I. Effects of l-dopa on the locomotor activity in rats pre-treated with 6-hydroxydopamine. Nat. New Biol. 234 (1971) 157-159
52. Wiechmann A.F., and O'Steen W.K. Melatonin increases photoreceptor susceptibility to light-induced damage. Invest. Optahalmol. Vis. Sci. 33 6 (1992) 1894-1902
53. Willis G.L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect. 18 7 (2005) 437-444
54. Willis G.L. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function. Behav. Brain Res. (2005) 148-160
55. Willis, G.L., in press. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Reviews in the Neurosciences.
56. Willis G.L., and Smith G.C. Amine accumulation in behavioural pathology. Brain Res. Rev. 9 (1985) 109-132
57. Willis G.L., and Armstrong S.M. Orphan neurones and amine excess; the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res. Rev. 27 (1998) 177-242
58. Willis G.L., and Armstrong S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. 66 5 (1999) 785-795
59. Willis G.L., and Robertson A.D. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral, 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol. Biochem. Behav. 79 3 (2004) 413-429
60. Willis G.L., and Robertson A.D. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Pharmacol. Biochem. Behav. 80 (2005) 9-26
61. Willis G.L., and Turner E.J.D. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light therapy: a case series study. Chronobiol. Int. 24 3 (2007) 521-537
62. Willis G.L., Singer G., and Evans B.K. Intracranial injections of 6-OHDA: comparison of the catecholamine depleting effects of different volumes and concentrations. Pharmacol. Biochem. Behav. 5 (1976) 207-213
63. Willis, G.L., Kelly, A.M.A., Kennedy, G.A., in press. Compromised circadian function in Parkinson's disease: Enucleation augments disease severity in the unilateral model. Behav. Brain Res.
64. Yilmaz T., Naziroglu M., Celebi S., Ozercan H.I., and Kukner A.S. Administration of high dose intravitral melatonin degenerates retinal cells in guinea pigs. Pathophysiology 11 (2004) 107-111
65. Zigmond M.J., and Stricker E.M. Deficits in feeding behaviour after intraventricular injection of 6-hydroxydopamine in rats. Science, 177 (1972) 1211-1214